Journal · Updated 2026-08-11
CagriSema: Novo's Next Act — the Amylin Combination and Its Roughly 23% Result
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
The short answer
CagriSema is Novo Nordisk's escalation: weekly semaglutide 2.4 mg co-formulated with cagrilintide 2.4 mg, an amylin analog — a second satiety hormone pathway stacked on the GLP-1 — whose phase-3 REDEFINE-1 readout showed roughly 22.7% average loss at 68 weeks in the primary analysis: ahead of semaglutide alone (14.9%) and of tirzepatide's 20.9% arm on cross-trial squinting, yet famously short of the ~25% Novo had guided markets to expect, a miss that moved share prices more than science. REDEFINE-2 added a T2D result in the mid-teens. Status: not approved, not purchasable — regulatory submissions and further readouts are the 2026 story — and the standing warning inherits from retatrutide's page verbatim: anything sold today as "CagriSema," "cagrilintide," or an amylin blend is gray-market research chemistry with no legal compounding lane and no place in a rational plan.
Why amylin, and what to do meanwhile
The mechanism bet: amylin is the pancreas's co-released satiety signal — slowing gastric emptying and acting on brainstem appetite circuits through different receptors than GLP-1 — so combining analogs of both aims at additive appetite control without simply raising one pathway's dose and its side effects. The readout's nuance worth keeping: trial-conduct details (flexible dosing protocols, adherence patterns) muddied the headline enough that analysts argued the molecule's ceiling remains unproven in either direction — a genuinely open scientific question the confirmatory program will answer. The practical translation for a 2026 buyer is the pipeline pages' constant refrain: today's approved tools already deliver 15–21% studied results at prices this site tracks daily; waiting for a marginally better drug costs a year of treatable months, and switching later is routine. Watch the space through the pipeline tracker; treat any current "CagriSema source" as the scam it is; and let the only medicine you take be the kind with a label.
Questions people ask
What is CagriSema and how well does it work?
Novo's phase-3 combination of semaglutide 2.4 mg with cagrilintide 2.4 mg (an amylin analog): REDEFINE-1 reported roughly 22.7% average loss at 68 weeks — ahead of semaglutide alone, short of Novo's ~25% target. A T2D trial added mid-teens results. It is not yet approved or purchasable.
When will CagriSema be available?
Regulatory submissions and confirmatory readouts are the current phase; availability follows approval, which hasn't happened. Timelines are the manufacturer's to announce — and any seller offering it today is offering unregulated research chemistry, not the drug.
Can I buy cagrilintide from peptide sites now?
Only as gray-market research chemicals — no approval, no legal compounding lane, no quality oversight, unknown dosing safety. The rational 2026 move is an approved 15–21% drug today (at prices from $129–$449 across our rankings) and a routine switch later if the combination earns it.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.